Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

- Cheng, Qinglu, Cunningham, Evan B., Hellard, Margaret, Bruggmann, Philip, Marks, Philippa, Lacombe, Karine, Stedman, Catherine, Read, Phillip, Hajarizadeh, Behzad, Dunlop, Adrian J., Conway, Brian, Feld, Jordan J., Shih, Sophy, Dore, Gregory J., Grebely, Jason, SIMPLIFY and D3FEAT Study Groups,, Amin, Janaki, Bruneau, Julie, Artenie, Adelina A., Powis, Jeff, Litwin, Alain H., Cooper, Curtis, Dalgard, Olav

Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study

- Wheeler, Alice, Valerio, Heather, Matthews, Gail V., Dunlop, Adrian J., Gorton, Carla, Hayllar, Jeremy, Alavi, Maryam, Murray, Carolyn, Marks, Phillipa, Silk, David, Degenhardt, Louisa, Dore, Gregory J., Cunningham, Evan B., Grebely, Jason, Martinello, Marianne, Barocas, Joshua A., Colledge-Frisby, Samantha, Treloar, Carla, Amin, Janaki, Henderson, Charles, Read, Phillip

Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study

- Grulich, Andrew E., Jin, Fengyi, Vickers, Tobias, McNulty, Anna, Smith, David J., Dharan, Nila J., Selvey, Christine, Power, Cherie, Price, Karen, Zablotska, Iryna, Baker, David A., Bloch, Mark, Bavinton, Benjamin R., Brown, Katherine, Carmody, Christopher J., Carr, Andrew, Chanisheff, Daniel, Doong, Nicholas, Finlayson, Robert, Lewis, David A., Lusk, Josephine, Martin, Sarah, Ooi, Catriona, Yeung, Barbara, Read, Phillip, Ryder, Nathan, Smith, Don, Soo, Clara Tuck Meng, Templeton, David J., Vlahakis, Emmanuel, Guy, Rebecca, Hammoud, Mohamed A., Amin, Janaki, Cabrera, Gesalit, Clackett, Shawn, Ogilvie, Erin, Vaccher, Stefanie

Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study

- Valerio, Heather, Alavi, Maryam, Read, Phillip, Marks, Philippa, Degenhardt, Louisa, Hayllar, Jeremy, Reid, David, Gorton, Carla, Lam, Thao, Dore, Gregory J., Grebely, Jason, Silk, David, Treloar, Carla, Martinello, Marianne, Milat, Andrew, Dunlop, Adrian, Holden, Jo, Henderson, Charles, Amin, Janaki

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

- Cunningham, Evan B., Amin, Janaki, Dunlop, Adrian J., Norton, Briana, Litwin, Alain H., Hajarizadeh, Behzad, Thurnheer, Maria Christine, Dillon, John F., Weltman, Martin, Shaw, David, Bruggmann, Philip, Gane, Edward, Feld, Jordan J., Fraser, C, Marks, P, Applegate, TL, Quiene, S, Siriragavan, S, Matthews, GV, Dore, GJ, Grebely, J, Bruneau, Julie, Dalgard, Olav, Powis, Jeff, Hellard, Margaret, Cooper, Curtis, Read, Phillip, Conway, Brian

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

- Grulich, Andrew E., Guy, Rebecca, Amin, Janaki, Jin, Fengyi, Selvey, Christine, Holden, Jo, Schmidt, Heather-Marie A., Zablotska, Iryna, Price, Karen, Whittaker, Bill, Chant, Kerry, Cooper, Craig, McGill, Scott, Telfer, Barbara, Yeung, Barbara, Levitt, Gesalit, Ogilvie, Erin E., Dharan, Nila J., Hammoud, Mohammed A.Stefanie, Vaccher, Stefanie, Ryder, Nathan

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

- Cunningham, Evan B., Hajarizadeh, Behzad, Swan, Tracy, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Bruneau, Julie, Midgard, Håvard, Bourgeois, Stefan, Dalgard, Olav, Thurnheer, Maria Christine, Dore, Gregory J., Grebely, Jason, Amin, Janaki, Hellard, Margaret, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study

- Midgard, Håvard, Hajarizadeh, Behzad, Hellard, Margaret, Robaeys, Geert, Thurnheer, Marcia C., Weltman, Martin, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Dore, Gregory J., Dalgard, Olav, Grebely, Jason, Cunningham, Evan B., Conway, Brian, Backmund, Markus, Bruggmann, Philip, Bruneau, Julie, Bourgeois, Stefan, Dunlop, Adrian, Foster, Graham R.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

- Grebely, Jason, Dalgard, Olav, Amin, Janaki, Marks, Philippa S., Quiene, Sophie, Applegate, Tanya L., Weltman, Martin, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Bruneau, Julie, Midgard, Håvard, Cunningham, Evan B., Hajarizadeh, Behzad, Foster, Graham R., Bruggmann, Philip, Conway, Brian, Backmund, Markus, Robaeys, Geert, Swan, Tracy

The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study

- Swart, Alexander, Burns, Lucinda, Mao, Limin, Grulich, Andrew E., Amin, Janaki, O'Connell, Dianne L., Meagher, Nicola S., Randall, Deborah A., Degenhardt, Louisa, Vajdic, Claire M.

Predictors of deferral of treatment for hepatitis C infection in Australian clinics

- Gidding, Heather F., Law, Matthew G., Amin, Janaki, MacDonald, Graeme A., Sasadeusz, Joe J., Levett-Jones, Tracy L., Strasser, Simone I., George, Jacob, Dore, Gregory J.